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Abstract
Medicare Part D beneficiaries with higher out-of-pocket costs are more likely to delay starting or not start
a recommended specialty drug when newly diagnosed with leukemia. Policy changes are needed to
ensure optimal access to specialty medications under Medicare Part D.
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American Journal of Managed Care, Volume 22, Number 4 (Supplement), March 18, 2016
KEY FINDINGS: Medicare Part D beneficiaries with higher out-of-pocket costs are more likely to delay starting or not
start a recommended specialty drug when newly diagnosed with leukemia. Policy changes are needed to ensure optimal
access to specialty medications under Medicare Part D.

THE QUESTION

THE FINDINGS

Does high cost sharing in Medicare Part D drug plans affect

The first 30-day prescription fill of TKI had a mean price
of $6,800; non-subsidized patients were required to pay
approximately $2,600 out-of-pocket for the initial fill, while
low-income subsidy (LIS) patients paid $5 or less. The high
out-of-pocket costs of the first fill pushed non-subsidized
patients out of the initial coverage phase and into the
coverage gap phase.

whether and how quickly patients initiate a recommended
and life-extending drug treatment? LDI Senior Fellows

Jalpa Doshi, Pengxiang Li and colleagues assess whether

Medicare patients newly diagnosed with chronic myeloid
leukemia (CML) and subject to significant coinsurance, take

longer to initiate tyrosine kinase inhibitors (TKI) treatment
than low-income (subsidized) Medicare patients subject to
a nominal copayment. Oral TKIs allow most patients with
CML to enjoy a near-normal life expectancy, and no lowercost option exists.

The complexity of the Medicare Part D benefits structure

makes this research particularly relevant. In 2011-2015, non-

subsidized Medicare beneficiaries who needed a specialty

drug faced coinsurance of 25%- 33% in the ‘initial coverage’
phase and 45%-50% in the ‘coverage gap’, also known

as the ‘donut hole’. After patients reach a ‘catastrophic
coverage limit’ ($4,550-$4,700 from 2011-2015), they pay
5% coinsurance for the rest of that calendar year.

Non-subsidized beneficiaries were less likely than LIS
beneficiaries to initiate TKI treatment within 6 months of
their diagnosis with CML – 45% versus 67% respectively.
Non-subsidized beneficiaries who did initiate TKI treatment
took more than twice as long as LIS beneficiaries to do so –
50.9 days versus 23.7 days respectively.
The patient’s subsidy status remained highly associated
with TKI initiation even when the authors controlled for
sociodemographic, clinical and plan characteristics. These
findings suggest that high cost sharing may impede access
to life saving specialty drug treatment. It should be noted,
however, that this was a cross-sectional analysis. The
study documents associations and cannot establish a causal
relationship between out-of-pockets costs and treatment
initiation.
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THE IMPLICATIONS

THE STUDY

This study demonstrates how high out-of-pocket costs may
limit or delay initiation of high-value treatments under
Medicare Part D. It shows that the one-size-fits-all cost
sharing in Medicare Part D plans, where cost sharing is
directly a function of the medication cost, may serve as a
barrier to patient initiation of specialty medications.

The authors used the 2011-2013 Medicare Chronic Condition
Data Warehouse files, which contain data on all fee-for-service
Medicare beneficiaries in the U.S. They identified 1,053 newly
diagnosed CML patients using a series of claims-based selection
criteria. The main outcome was the time to TKI initiation, or
the number of days elapsed between the first date of CML
diagnosis and the date that the first TKI prescription was filled.
The authors compared initiation of TKI treatment among nonsubsidy Medicare beneficiaries against a comparison group of
newly-diagnosed LIS patients. Extensive sensitivity analyses
related to sample selection criteria, measuring time to TKI
initiation, and analytic techniques confirmed the robustness of
the findings.

This is the first study to utilize a full set of national Medicare
Part A, B, and D fee-for-service claims linked with Part D
plan and formulary information to explore the relationship
between high cost sharing and access to specialty cancer
drugs. Most prior evidence is out-of-date and focused on
privately insured populations with lower levels of cost
sharing.
The mean out-of-pocket payment for the first TKI
prescription fill far exceeded the average monthly Social
Security benefit (less than $1,350), which is the main source
of income for many Medicare beneficiaries. Although the
Affordable Care Act is meant to close the Part D coverage
gap by 2020, patients will still be responsible for high rates of
coinsurance, effectively extending the cost sharing currently
in place for specialty drugs during the initial coverage phase.
The authors suggest several policy fixes to protect patients
against inordinately high out-of-pocket costs. These
include: reducing beneficiary cost-sharing responsibility
for drugs that have higher demonstrated efficacy and value;
establishing an out-of-pocket spending maximum similar to
many private insurance plans; and allowing beneficiaries to
distribute total out-of-pocket costs more evenly throughout
the year.

THE STUDY
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